This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 6.45% and 45.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up
by Zacks Equity Research
FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 3.30% and 2.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -20.18% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 1.59% and 5.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 4.35% and -1.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Revance Therapeutics (RVNC) Ahead of Earnings?
by Zacks Equity Research
Revance Therapeutics (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 6.14% and 12.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Revance Therapeutics, Inc. (RVNC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 9.24% and 6.89%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
by Zacks Equity Research
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
Is a Surprise Coming for Revance (RVNC) This Earnings Season?
by Zacks Equity Research
Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA
by Zacks Equity Research
AbbVie's (ABBV) sBLA for expanding the label of Botox for use in pediatric patients with neurogenic detrusor overactivity gets acceptance from the FDA.
Revance's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
How Revance (RVNC) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.